ASH 2022 Conference Coverage

 

ASH 2022 Conference Coverage
R

ASH 2022: Real-World Comparison of Time to Next Treatment for Patients With CLL Initiated on 1L Treatment With Ibrutinib vs. Acalabrutinib

By ASH 2022 Conference Coverage FEATURING Ryan Jacobs
By ASH 2022 Conference Coverage FEATURING Ryan Jacobs
121 views
January 13, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
Leukemia
10:42
ASH 2022 Conference Coverage

Results From the Phase 3 ALPINE Study: Zanubrutinib vs. Ibrutinib in…

Feat. J. Brown
05:06
ASH 2022 Conference Coverage

ASH 2022 Ponatinib & Blinatumomab for Patients With R/R Ph+ ALL …

Feat. W. Macaron
03:41
ASH 2022 Conference Coverage

ASH 2022: Venetoclax Combined With Cladribine, Idarubicin, Cytarabin…

Feat. G. Borthakur
11:00
ASH 2022 Conference Coverage

ASH 2022 Updates and Highlights in CML

Feat. E. Atallah
14:41
ASH 2022 Conference Coverage

Clinical Implications of the QUAZAR AML-001 Trial: Oral AZA Maintena…

Feat. P. Michael
19:04
ASH 2022 Conference Coverage

ASH 2022: Real-World Comparison of Time to Next Treatment for Patien…

Feat. R. Jacobs
07:16
ASH 2022 Conference Coverage

CAPTIVATE Study Updates: CLL Treatment Outcomes After Undetectable M…

Feat. C. Tam
14:37
ASH 2022 Conference Coverage

ASH 2022 Results of the ASC4MORE Study: Asciminib Add-On to Imatinib…

Feat. G. Saglio
11:30
ASH 2022 Conference Coverage

ASH 2022 Post-Allogeneic Stem Cell Transplant Outcomes in Patients T…

Feat. A. Jain
06:57
ASH 2022 Conference Coverage

ASH 2022 NX-2127-001, a First-in-Human Trial of NX-2127, a BTK-Targe…

Feat. A. Danilov
13:16
ASH 2022 Conference Coverage

Experts Discuss Key Updates in CLL

Feat. S. O'Brien, C. Coombs
10:41
ASH 2022 Conference Coverage

ASH 2022 Triplet Combination of Azacitidine, Venetoclax, and Gilteri…

Feat. N. Short
06:22
ASH 2022 Conference Coverage

ASH 2022 The Addition of Inotuzumab Ozogamicin to Hyper-CVAD + Blina…

Feat. N. Short
07:38
ASH 2022 Conference Coverage

ASH 2022 Ponatinib & Blinatumomab for Pts With Newly Diagnosed P…

Feat. N. Short
11:05
ASH 2022 Conference Coverage

ASH 2022 Preliminary Safety & Efficacy From the Phase 2 APEX Stu…

Feat. D. DeAngelo
09:45
ASH 2022 Conference Coverage

ASH 2022 Treatment of CLL-Associated Autoimmune Cytopenias and Outco…

Feat. K. Rogers
11:10
ASH 2022 Conference Coverage

ASH 2022 Updated Phase 2b Results of Venetoclax With FLAG-IDA in R/R…

Feat. M. Konopleva
08:14
ASH 2022 Conference Coverage

ASH 2022 Single vs. Double Induction With "7+3" Containing…

Feat. C. Röllig
07:48
ASH 2022 Conference Coverage

ASH 2022 Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Fe…

Feat. C. Röllig
27:09
ASH 2022 Conference Coverage

ASH 2022: What Is Complete HLA Match in 2022?

Feat. S. Spellman
11:12
ASH 2022 Conference Coverage

ASH 2022 Gene Edited Off-the-Shelf NK Cells for Treating Hematologic…

Feat. J. Miller
08:00
ASH 2022 Conference Coverage

ASH 2022 Phase III ASAP Trial Results: Sequential Conditioning &…

Feat. J. Schetelig
15:43
ASH 2022 Conference Coverage

ASH 2022 UK NCRI AML19 Trial: FLAG-Ida With Gemtuzumab Ozogamicin Im…

Feat. N. Russell
20:03
ASH 2022 Conference Coverage

ASH 2022: Post-Remission Outcomes in Patients With AML Are Similar B…

Feat. M. Hochman
09:54
ASH 2022 Conference Coverage

ASH 2022 Phase II Study of Myeloablative 8/8- or 7/8-Matched AlloSCT…

Feat. A. Hoover
07:05
ASH 2022 Conference Coverage

ASH 2022: Lintuzumab-Ac225 in Combination With Intensive Chemo Yield…

Feat. S. Abedin
10:28
ASH 2022 Conference Coverage

ASH 2022 Phase 1 Study With the Novel Bcl-2 Inhibitor BGB-11417 as M…

Feat. C. Cheah
06:20
ASH 2022 Conference Coverage

Consolidation With Allogeneic HCT Improved Survival Outcomes of Adul…

Feat. I. Aldoss
16:32
ASH 2022 Conference Coverage

ASH 2022 Phase 3 GLOW Study: Residual Disease Kinetics Among CLL Pat…

Feat. C. Utoft Niemann
04:07
ASH 2022 Conference Coverage

ASH 2022 Novel Combination of Clinical Menin Inhibitor Ziftomenib an…

Feat. S. Balasubramanian
09:33
ASH 2022 Conference Coverage

ASH 2022 4-Year Follow-up Data on Combined Ibrutinib and Venetoclax …

Feat. N. Jain
05:38
ASH 2022 Conference Coverage

ASH 2022 Preclinical In Vivo Activity of the Menin Inhibitor Ziftome…

Feat. S. Tasian
06:23
ASH 2022 Conference Coverage

ASH 2022 Comparing Venetoclax & Azacitidine to Conventional Indu…

Feat. A. Fathi
06:04
ASH 2022 Conference Coverage

ASH 2022 Final Analysis of the CLL2-GIVe Trial: Obinutuzumab, Ibruti…

Feat. S. Stilgenbauer
05:12
ASH 2022 Conference Coverage

ASH 2022 Asciminib as Initial Therapy for Patients With CML-CP: H. J…

Feat. E. Atallah
09:42
ASH 2022 Conference Coverage

Transplant in AML With MRD: Proceed or Defer?

Feat. C. Craddock
15:42
ASH 2022 Conference Coverage

ASH 2022: Reduced Venetoclax Exposition to 7 Days of Azacitidine Is …

Feat. C. Willekens
07:37
ASH 2022 Conference Coverage

ASH 2022: More Than 10 Years Follow-Up of Frontline TKI Therapy in P…

Feat. F. Haddad
07:41
ASH 2022 Conference Coverage

ASH 2022 Effectiveness of TKIs in Patients With CML-CP After Two or …

Feat. D. Žáčková
08:19
ASH 2022 Conference Coverage

ASH 2022 Results From the Phase 1/2 BRUIN Study: Safety & Tolera…

Feat. N. Shah
08:12
ASH 2022 Conference Coverage

ASH 2022 Final Analysis Results From the InformCLL Registry: Real-Wo…

Feat. N. Ghosh
11:38
ASH 2022 Conference Coverage

ASH 2022 ECOG-ACRIN-E1910 Randomized Phase III NCTN Trial: Blinatumo…

Feat. M. Litzow
07:30
ASH 2022 Conference Coverage

ASH 2022 Efficacy & Safety of Ruxolitinib for Treatment of Sympt…

Feat. E. Padron
08:00
ASH 2022 Conference Coverage

ASH 2022 Contemporary Guidelines for Diagnosis and Genomic Classific…

Feat. I. Iacobucci
08:02
ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

Feat. S. Holtan
04:55
ASH 2022 Conference Coverage

ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamib…

Feat. E. Stein
11:52
ASH 2022 Conference Coverage

ASH 2022 Real-World OS and TTNT by 1L Therapy (BTKi and BCL2i) in Pa…

Feat. W. Archibald, C. Wang
05:33
ASH 2022 Conference Coverage

ASH 2022: Phase II Study of Inotuzumab Ozogamicin for the Treatment …

Feat. J. Senapati
10:39
ASH 2022 Conference Coverage

ASH 2022: Splicing Factor Gene Mutations Do Not Affect Outcomes in N…

Feat. J. Senapati
07:43
ASH 2022 Conference Coverage

ASH 2022 The Menin Inhibitor Revumenib (SNDX-5613) Leads to Durable …

Feat. G. Issa
08:57
ASH 2022 Conference Coverage

ASH 2022 Impact of Allelic State on Overall Survival in TP53-Mutant …

Feat. J. Bewersdorf